The Role of Neuropeptide Y in Cardiovascular Health and Disease

Overview

Journal Front Physiol

Date 2018 Oct 5

PMID 30283345

Citations 82

Authors

Cheryl M J Tan

Peregrine Green

Nidi Tapoulal

Adam J Lewandowski

Paul Leeson

Neil Herring

Affiliations

Soon will be listed here.

Abstract

Neuropeptide Y (NPY) is an abundant sympathetic co-transmitter, widely found in the central and peripheral nervous systems and with diverse roles in multiple physiological processes. In the cardiovascular system it is found in neurons supplying the vasculature, cardiomyocytes and endocardium, and is involved in physiological processes including vasoconstriction, cardiac remodeling, and angiogenesis. It is increasingly also implicated in cardiovascular disease pathogenesis, including hypertension, atherosclerosis, ischemia/infarction, arrhythmia, and heart failure. This review will focus on the physiological and pathogenic role of NPY in the cardiovascular system. After summarizing the NPY receptors which predominantly mediate cardiovascular actions, along with their signaling pathways, individual disease processes will be considered. A thorough understanding of these roles may allow therapeutic targeting of NPY and its receptors.

Citing Articles

The brain-heart axis: integrative cooperation of neural, mechanical and biochemical pathways.

Valenza G, Matic Z, Catrambone V Nat Rev Cardiol. 2025; .

PMID: 40033035 DOI: 10.1038/s41569-025-01140-3.

Sprouting sympathetic fibres release CXCL16 and norepinephrine to synergistically mediate sensory neuronal hyperexcitability in a rodent model of neuropathic pain.

Wang C, Di A, Wu Y, Liu M, Wei M, Liang Z Br J Anaesth. 2025; 134(3):804-816.

PMID: 39848871 PMC: 11867076. DOI: 10.1016/j.bja.2024.10.019.

Neuropeptide Y in cancer-biological functions and potential clinical implications.

Sigorski D, Sejda A, Abualsaud N, Krawczyk E, Izycka-Swieszewska E, Kitlinska J Cancer Metastasis Rev. 2025; 44(1):21.

PMID: 39760953 PMC: 11703900. DOI: 10.1007/s10555-024-10237-z.

Case Report: The unrelenting journey-successful resolution of catecholaminergic polymorphic ventricular tachycardia (CPVT) through right cardiac sympathetic denervation in a teenager after left cardiac sympathetic denervation.

Leung H, Kwok S, Lau M, Lee L, Tsao S Front Cardiovasc Med. 2024; 11:1477359.

PMID: 39735866 PMC: 11671521. DOI: 10.3389/fcvm.2024.1477359.

Higher order interaction analysis quantifies coordination in the epigenome revealing novel biological relationships in Kabuki syndrome.

Cuvertino S, Garner T, Martirosian E, Walusimbi B, Kimber S, Banka S Brief Bioinform. 2024; 26(1).

PMID: 39701600 PMC: 11658816. DOI: 10.1093/bib/bbae667.

References

Li L, Jonsson-Rylander A, Abe K, Zukowska Z . Chronic stress induces rapid occlusion of angioplasty-injured rat carotid artery by activating neuropeptide Y and its Y1 receptors. Arterioscler Thromb Vasc Biol. 2005; 25(10):2075-80. DOI: 10.1161/01.ATV.0000179601.19888.19. View

Lundberg J, Terenius L, Hokfelt T, Martling C, Tatemoto K, Mutt V . Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 1982; 116(4):477-80. DOI: 10.1111/j.1748-1716.1982.tb07171.x. View

Tatemoto K, Carlquist M, Mutt V . Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982; 296(5858):659-60. DOI: 10.1038/296659a0. View

Missouris C, Grouzmann E, Buckley M, Barron J, Macgregor G, Singer D . How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. Clin Sci (Lond). 1998; 94(6):591-9. DOI: 10.1042/cs0940591. View

Potter E . Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y?. Neurosci Lett. 1985; 54(2-3):117-21. DOI: 10.1016/s0304-3940(85)80065-3. View

Robich M, Matyal R, Chu L, Feng J, Xu S, Laham R . Effects of neuropeptide Y on collateral development in a swine model of chronic myocardial ischemia. J Mol Cell Cardiol. 2010; 49(6):1022-30. PMC: 2975818. DOI: 10.1016/j.yjmcc.2010.08.022. View

Anderson M . Calmodulin kinase signaling in heart: an intriguing candidate target for therapy of myocardial dysfunction and arrhythmias. Pharmacol Ther. 2005; 106(1):39-55. DOI: 10.1016/j.pharmthera.2004.11.002. View

Han C, Wang X, Fiscus R, Gu J, McDonald J . Changes in cardiac neuropeptide Y after experimental myocardial infarction in rat. Neurosci Lett. 1989; 104(1-2):141-6. DOI: 10.1016/0304-3940(89)90344-3. View

Morris M, Cox H, Lambert G, Kaye D, Jennings G, Meredith I . Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans. Hypertension. 1997; 29(1 Pt 1):137-43. DOI: 10.1161/01.hyp.29.1.137. View

10.

Kassis S, Olasmaa M, Terenius L, Fishman P . Neuropeptide Y inhibits cardiac adenylate cyclase through a pertussis toxin-sensitive G protein. J Biol Chem. 1987; 262(8):3429-31. View

11.

Bell D, Allen A, Kelso E, Balasubramaniam A, McDermott B . Induction of hypertrophic responsiveness of cardiomyocytes to neuropeptide Y in response to pressure overload. J Pharmacol Exp Ther. 2002; 303(2):581-91. DOI: 10.1124/jpet.102.038448. View

12.

Nicholl S, Bell D, Spiers J, McDermott B . Neuropeptide Y Y(1) receptor regulates protein turnover and constitutive gene expression in hypertrophying cardiomyocytes. Eur J Pharmacol. 2002; 441(1-2):23-34. DOI: 10.1016/s0014-2999(02)01440-1. View

13.

Dubois-Rande J, Comoy E, Merlet P, Benvenuti C, Carville C, Hittinger L . Relationship among neuropeptide Y, catecholamines and haemodynamics in congestive heart failure. Eur Heart J. 1992; 13(9):1233-8. DOI: 10.1093/oxfordjournals.eurheartj.a060342. View

14.

Acuna-Goycolea C, Tamamaki N, Yanagawa Y, Obata K, van den Pol A . Mechanisms of neuropeptide Y, peptide YY, and pancreatic polypeptide inhibition of identified green fluorescent protein-expressing GABA neurons in the hypothalamic neuroendocrine arcuate nucleus. J Neurosci. 2005; 25(32):7406-19. PMC: 6725307. DOI: 10.1523/JNEUROSCI.1008-05.2005. View

15.

Dzau V, Braun-Dullaeus R, Sedding D . Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002; 8(11):1249-56. DOI: 10.1038/nm1102-1249. View

16.

Zhu X, Gillespie D, Jackson E . NPY1-36 and PYY1-36 activate cardiac fibroblasts: an effect enhanced by genetic hypertension and inhibition of dipeptidyl peptidase 4. Am J Physiol Heart Circ Physiol. 2015; 309(9):H1528-42. PMC: 4666977. DOI: 10.1152/ajpheart.00070.2015. View

17.

Schwertfeger E, Klein T, Vonend O, Oberhauser V, Stegbauer J, Rump L . Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369(5):455-61. DOI: 10.1007/s00210-004-0930-9. View

18.

Pernow J, Ohlen A, Hokfelt T, Nilsson O, Lundberg J . Neuropeptide Y: presence in perivascular noradrenergic neurons and vasoconstrictor effects on skeletal muscle blood vessels in experimental animals and man. Regul Pept. 1987; 19(5-6):313-24. DOI: 10.1016/0167-0115(87)90173-x. View

19.

Yi M, Li H, Wu Z, Yan J, Liu Q, Ou C . A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans. Cell Physiol Biochem. 2018; 45(1):88-107. DOI: 10.1159/000486225. View

20.

Ali E, Hua J, Wilson C, Tallis G, Zhou F, Rychkov G . The glucagon-like peptide-1 analogue exendin-4 reverses impaired intracellular Ca(2+) signalling in steatotic hepatocytes. Biochim Biophys Acta. 2016; 1863(9):2135-46. DOI: 10.1016/j.bbamcr.2016.05.006. View